| Iondrive Limited (ION) ORDINARY FULLY PAID |
Materials |
$51 |
Positive Techno-Economic Evaluation for REE Recycling
|
17 Nov 2025 8:28AM |
$0.045 |
$0.039 |
fallen by
13.33%
|
|
ION - Price-sensitive ASX Announcement
Full Release
Key Points
- Iondrive Limited completed a Phase 1 techno-economic evaluation for its IONSolvTM technology platform for a 2ktpa modular REE recycling plant.
- The study confirms that the IONSolvTM process can derive value from waste magnets, supporting a scalable modular rollout across U.S. sites.
- Economic modeling indicates a post-tax NPV of US $7M, a post-tax IRR of 46%, and a payback period of 2.6 years.
- The Phase 1 study found that the average annual production rate is approximately 115 tonnes of mixed rare-earth oxides over a ten-year operating life.
- Phase 2 laboratory validation is underway to confirm process assumptions and refine economic modeling before plant engineering.
- The IONSolvTM technology is a Deep Eutectic Solvent (DES) process for REE recovery and is noted for complementing other recycling initiatives for batteries and solar panels.
- The study suggests that Iondrive can help reduce North America's reliance on imported REEs and strengthen critical mineral supply chains.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Ansell Limited (ANN) ORDINARY FULLY PAID |
Health Care |
$4,555 |
Notification regarding unquoted securities - ANN
|
17 Nov 2025 8:28AM |
$36.560 |
$32.460 |
fallen by
11.21%
|
|
| Calix Limited (CXL) ORDINARY FULLY PAID |
Materials |
$73 |
Joint Development Agreement (JDA) with Rio Tinto for Zesty
|
17 Nov 2025 8:28AM |
$0.465 |
$0.340 |
fallen by
26.88%
|
|
CXL - Price-sensitive ASX Announcement
Full Release
Key Points
- Calix Limited has executed a Joint Development Agreement (JDA) with Rio Tinto for the Zesty Green Iron Demonstration Plant.
- Rio Tinto will contribute over $35 million in cash and in-kind support to the project.
- The project aims to demonstrate and commercialize Calix's Zero Emissions Steel Technology (Zesty).
- The Zesty Demonstration Plant will be located in Kwinana, Western Australia.
- The project is supported by a grant of up to $44.9 million from the Australian Renewable Energy Agency (ARENA).
- Rio Tinto's contribution includes technical support, engineering services, and the provision of Pilbara Iron Ores.
- The JDA allows Rio Tinto to potentially take up shares in a Zesty subsidiary business.
- The Zesty technology aims to produce green iron and steel using electric heating and hydrogen reduction.
- The project is expected to reach a Final Investment Decision (FID) by 2026.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Radiopharm Theranostics Limited (RAD) ORDINARY FULLY PAID |
Health Care |
$50 |
RAD Announces 50% Enrollment in Phase 2b Trial of RAD101
|
17 Nov 2025 8:28AM |
$0.022 |
$0.014 |
fallen by
36.36%
|
|
RAD - Price-sensitive ASX Announcement
Full Release
Key Points
- Radiopharm Theranostics reached 50% enrollment in Phase 2b trial of RAD101.
- RAD101 targets fatty acid synthase overexpressed in tumors.
- Early data shows promising tumor uptake in brain metastases.
- Phase 2b trial results expected in first half of 2026.
- RAD101 has FDA Fast Track Designation.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Pro Medicus Limited (PME) ORDINARY FULLY PAID |
Health Care |
$16,949 |
Update - Notification of buy-back - PME
|
17 Nov 2025 8:28AM |
$248.830 |
$162.240 |
fallen by
34.80%
|
|
| DataWorks Group Limited (DWG) ORDINARY FULLY PAID |
Information Technology |
$12 |
Strong BetStop Outcomes and Operational Excellence Reported
|
17 Nov 2025 8:28AM |
$0.056 |
$0.120 |
risen by
114.29%
|
|
| CSL Limited (CSL) ORDINARY FULLY PAID |
Health Care |
$55,741 |
Update - Notification of buy-back - CSL
|
17 Nov 2025 8:28AM |
$181.810 |
$116.390 |
fallen by
35.98%
|
|
| Zip Co Limited (ZIP) ORDINARY FULLY PAID |
Financials |
$3,289 |
Update - Notification of buy-back - ZIP
|
17 Nov 2025 8:28AM |
$3.140 |
$2.640 |
fallen by
15.92%
|
|
| Noxopharm Limited (NOX) ORDINARY FULLY PAID |
Health Care |
$25 |
First dose in HERACLES clinical trial Part Two
|
17 Nov 2025 8:27AM |
$0.090 |
$0.082 |
fallen by
8.89%
|
|
NOX - Price-sensitive ASX Announcement
Full Release
Key Points
- First dosing in HERACLES Part Two starts.
- SOF-SKNâ„¢ tested for autoimmune diseases.
- Trial conducted in Australia for tax benefits.
- Phase I trial evaluates safety and tolerability.
- Two cohorts receive daily doses for two weeks.
- Focus on real-world application of treatments.
- Noxopharm collaborates with Doherty Clinical Trials.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| HighCom Limited (HCL) ORDINARY FULLY PAID |
Industrials |
$16 |
HighCom Armor Business Update
|
17 Nov 2025 8:27AM |
$0.285 |
$0.115 |
fallen by
59.65%
|
|
| FSA Group Limited (FSA) ORDINARY FULLY PAID |
Financials |
$163 |
Update - Notification of buy-back - FSA
|
17 Nov 2025 8:27AM |
$1.235 |
$1.300 |
risen by
5.26%
|
|
| Brambles Limited (BXB) ORDINARY FULLY PAID |
Industrials |
$25,458 |
Update - Notification of buy-back - BXB
|
17 Nov 2025 8:27AM |
$23.660 |
$19.060 |
fallen by
19.44%
|
|
| L1 Long Short Fund Limited (LSF) ORDINARY FULLY PAID |
Financials |
$2,856 |
Net Tangible Asset Backing
|
17 Nov 2025 8:27AM |
$3.580 |
$4.500 |
risen by
25.70%
|
|
| Ophir High Conviction Fund (OPH) ORDINARY UNITS FULLY PAID |
Financials |
$568 |
Weekly NTA 14.11.2025
|
17 Nov 2025 8:26AM |
$3.250 |
$2.550 |
fallen by
21.54%
|
|
| Red Metal Limited (RDM) ORDINARY FULLY PAID |
Materials |
$52 |
Sybella REO Breakthrough Results From Ion Exchange Trials
|
17 Nov 2025 8:26AM |
$0.125 |
$0.135 |
risen by
8%
|
|
RDM - Price-sensitive ASX Announcement
Full Release
Key Points
- Red Metal Limited reported successful Ion Exchange trials at Sybella Rare Earth Project.
- The trials successfully separated rare earth elements (REE) from impurities such as iron and aluminium.
- A final Strip Liquor with very low impurities and a 9x enrichment of total rare earth oxide (TREO) content was achieved.
- The Ion Exchange process simplifies the flowsheet, potentially reducing capital and operating costs.
- The process increases REE recovery from Pregnant Leach Liquor to mixed rare earth carbonate (MREC) from approximately 93% to 99%.
- The simplified process offers reduced flowsheet complexity and lower alkali costs.
- Advanced comminution studies and weak-acid column heap leach tests are near completion.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Australian Clinical Labs Limited (ACL) ORDINARY FULLY PAID |
Health Care |
$438 |
Update - Notification of buy-back - ACL
|
17 Nov 2025 8:26AM |
$2.700 |
$2.350 |
fallen by
12.96%
|
|
| TerraCom Limited (TER) ORDINARY FULLY PAID |
Energy |
$126 |
Expected Coal Shipment Delays
|
17 Nov 2025 8:26AM |
$0.086 |
$0.069 |
fallen by
19.77%
|
|
TER - Price-sensitive ASX Announcement
Full Release
Key Points
- TerraCom Limited anticipates coal shipment delays for the December 2025 quarter due to rail and supply chain constraints.
- The Blair Athol Mine remains fully operational but logistics constraints might increase supply chain costs.
- Two shipments have already sailed, but significant coal stocks remain on-site and at the port.
- Reduced logistics availability is expected to lead to lower coal shipments and revenues for the quarter.
- The company is implementing initiatives to manage liquidity, such as prepayment arrangements and working capital funding options.
- TerraCom assures stakeholders that operational performance and market outlook remain strong.
- The situation is being closely monitored within TerraCom’s cashflow and liquidity management framework.
- The announcement was approved by the TerraCom Board for release.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Genetic Signatures Limited (GSS) ORDINARY FULLY PAID |
Health Care |
$14 |
2025 Annual General Meeting Chair Address & Presentation
|
17 Nov 2025 8:26AM |
$0.290 |
$0.060 |
fallen by
79.31%
|
|
GSS - Price-sensitive ASX Announcement
Full Release
Key Points
- Significant transformation and strategic realignment in FY2025.
- 66% increase in FY25 revenue with strong sales performance.
- Strategic focus on core products and U.S. market expansion.
- Leadership changes with new Directors and CEO appointment.
- Voting on resolutions including director re-elections and remuneration report.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Orora Limited (ORA) ORDINARY FULLY PAID |
Materials |
$1,795 |
Update - Notification of buy-back - ORA
|
17 Nov 2025 8:26AM |
$2.260 |
$1.465 |
fallen by
35.18%
|
|
| Genetic Signatures Limited (GSS) ORDINARY FULLY PAID |
Health Care |
$14 |
$4.4m R&D Tax Incentive Received
|
17 Nov 2025 8:26AM |
$0.290 |
$0.060 |
fallen by
79.31%
|
|
GSS - Price-sensitive ASX Announcement
Full Release
Key Points
- Genetic Signatures Limited received a $4.4 million R&D Tax Incentive refund.
- The refund was provided by the Australian Taxation Office.
- The incentive is part of the Australian Government's R&D tax program.
- The refund relates to eligible R&D activities conducted in the financial year ended 30 June 2025.
- Genetic Signatures Limited is a molecular diagnostics company focusing on infectious disease detection.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Lincoln Minerals Limited (LML) ORDINARY FULLY PAID |
Materials |
$40 |
Notification regarding unquoted securities - LML
|
17 Nov 2025 8:26AM |
$0.010 |
$0.014 |
risen by
40%
|
|
| Light & Wonder Inc. (LNW) CHESS DEPOSITARY INTERESTS 1:1 |
Consumer Discretionary |
$9,001 |
LNW - Form 3 (Ownership Update - Fine Capital)
|
17 Nov 2025 8:26AM |
$131.660 |
$109.700 |
fallen by
16.68%
|
|
| Dyno Nobel Limited (DNL) ORDINARY FULLY PAID |
Materials |
$6,678 |
Update - Notification of buy-back - DNL
|
17 Nov 2025 8:25AM |
$3.400 |
$3.810 |
risen by
12.06%
|
|
| Light & Wonder Inc. (LNW) CHESS DEPOSITARY INTERESTS 1:1 |
Consumer Discretionary |
$9,001 |
LNW - Form 8-K (Change in Bylaws)
|
17 Nov 2025 8:25AM |
$131.660 |
$109.700 |
fallen by
16.68%
|
|
| Light & Wonder Inc. (LNW) CHESS DEPOSITARY INTERESTS 1:1 |
Consumer Discretionary |
$9,001 |
LNW - SC 13G-A (Ownership Update - Caledonia)
|
17 Nov 2025 8:25AM |
$131.660 |
$109.700 |
fallen by
16.68%
|
|